Moderna (MRNA) earnings call transcripts

Management framed the quarter as evidence that international partnerships and cost discipline can support growth while the pipeline advances toward multiple pivotal readouts.

Management framed 2026 as a return to growth, while emphasizing disciplined costs and a diversified pipeline amid significant U.S. regulatory uncertainty.

Management framed the call around faster cost reductions and seasonal sales visibility, while acknowledging pipeline setbacks and deferring major investment decisions until break-even.